Immuron to present at the Military Health System Research Symposium
August 14, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it...
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
July 25, 2023 06:00 ET
|
Immuron Limited
Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced...
Immuron CEO, Steven Lydeamore to present at Bioshares
July 24, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief...
Immuron Business Update - Ateria Health launches Juvia™ in Australia
July 11, 2023 06:00 ET
|
Immuron Limited
Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in AustraliaNew clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to...
Immuron FY23 Sales increase 136% on FY22 Sales
July 05, 2023 06:00 ET
|
Immuron Limited
Highlights: Australian FY23 sales of A$1.16 M (478% increase on FY22 sales)USA FY23 Travelan® sales of A$643 k (28% increase on FY22 sales)Global FY23 sales of A$1.80 M (136% increase on FY22 sales) ...
Immuron Chairman Transition
June 30, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the...
Immuron Business Update: Letter to Shareholders
June 22, 2023 06:00 ET
|
Immuron Limited
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Initiates Recruitment of Travelan® Clinical Study
May 30, 2023 06:00 ET
|
Immuron Limited
Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
May 08, 2023 06:00 ET
|
Immuron Limited
Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND applicationUS Naval Medical Research Centre (NMRC) satisfactorily...
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
May 02, 2023 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...